Retinal vascular occlusive diseases (RVOD) include arterial and venous occlusions: retinal artery occlusions can be divided into two major types: central retinal artery occlusions (CRAO), and branch retinal artery occlusions (BRAO); retinal vein occlusions can be divided into central retinal vein occlusions (CRVO) and branch retinal vein occlusions (BRVO).
Summary: Elevated plasma homocysteine (Hcy) level is considered a risk factor for vascular diseases. In recent years, many scientific reports have suggested that hyperhomocystinemia may be associated with an increased risk of retinal vascular occlusive disease (RVOD). The prevalence of elevation of homocysteine in patients with a recent retinal vascular occlusion was compared to a health control group in this study. Forty-nine consecutive patients (22 M; 27 F) (age 26-85 years, mean 69) with diagnosis of retinal vascular occlusion were compared with 71 healthy controls. These patients underwent laboratory evaluation for plasma fasting total homocysteine, activated protein C resistance, protein C, protein S, antithrombin III, and antiphospholipid and anticardiolipin antibodies. The G20210 prothrombin gene mutation (FII G20210A) and Factor V Leiden mutation (FVL) were evaluated. None of these enrolled subjects had other prothrombic risk factors. The health control group consisted of healthy subjects from the general population, with no history or clinical evidence of retinal vascular disease, recruited during the same 2year period. High fasting homocystinemia (higher than 15 µmol/L) was detected in 24/49 subjects (48.9%) (P < .0005). There was a high prevalence of hyperhomocystinemia: these data suggest an association between RVOD and high fasting homocystinemia. Elevated homocysteine may be an independent risk factor, and its assessment may be important in the investigation, management, and follow-up of patients with RVOD. Further controlled studies are necessary to clarify the exact role of hyperhomocystinemia in RVOD and to evaluate the appropriate therapeutic approach. Key Words: Retinal vascular occlusive disease-Homocysteine-Risk factor. disease (5) . Yildirim and colleagues suggested an association between hyperhomocystinemia and RVOD, but didn't clarify the exact role of hyperhomocystinemia in RVOD (6) . From the study of Di Crecchio and colleagues emerges the hypothesis that the homocysteine plasma level is not to be considered a primary and independent risk factor for RVOD (7) . Boyd and colleagues failed to find a high prevalence of hyperhomocystinemia in CRVO patients (8) .
The aim of this study was to conduct a retrospective case-control study of a cohort of patients with retinal vascular occlusion, to investigate a possible relationship between RVOD and hyperhomocystinemia.
Homocysteine is an amino acid with a sulfhydryl group, formed from methionine and which metabolism is dependent on vitamins or vitamins derivatives (folate, vitamin B12, vitamin B6, and flavin adenine dinucleotide). Hyperhomocystinemia can give rise to a dysfunction in the endothelium of the vessel, with a proliferation of vascular smooth muscle and prothrombic hemostatic changes. Homocysteine levels are increased by dietary deficiency of folate and vitamins B6 and B12 and hence are potentially reversible. In the last year, many possible causes of HCY increase have been studied: lifestyles and physiologic determinants (male gender, old age, coffee, smoking, poor B vitamin status), drugs (anticonvulsant, metformin, methotrexate, omeprazole, theophylline, etc.), diseases (renal failure, hypothyroidism, diabetes type II, proliferative diseases, etc.), and genetic determinants (methylene tetrahydrofolate reductase [MTHFR] C677T and cystathionine beta-synthase (CBS) mutations).
Different collagen-vascular diseases may cause retinal vascular obstruction, including temporal arteritis, scleroderma, polyarteritis nodosa, lupus erythematosus, and inflammatory phlebitis.
Blood dyscrasias can result in hyperviscosity as a result of either an increased number of circulating cells (chronic leukemias, polycythemia) or change in plasma proteins (Waldenström's macroglobulinemia, multiple myeloma). Patients with malignant diseases are at substantial risk for thromboembolism, thought to result from tumor-induced hemostatic abnormalities leading to a hypercoagulable state (9) .
MATERIALS AND METHODS

Patients
We Table 1 . The patients were compared with 71 white healthy subjects comparable for age and gender, from the general population, with no history or clinical evidence of retinal vascular disease, recruited in the same geographical area during the same 2-year period. Demographic, cardiovascular risk factor, and diagnostic data were recorded for each subject based on a standardized format. To minimize the influence of the vascular event on plasma Hcy levels we included only cases diagnosed within 6 months before the study. These patients underwent laboratory evaluation for plasma fasting total homocysteine, activated protein C resistance, protein C, protein S, antithrombin III, antiphospholipid and anticardiolipin antibodies. The G20210 prothrombin gene mutation (FII G20210A) and Factor V Leiden mutation (FVL) were evaluated. Exclusion criteria were evidence of renal failure (three patients), genetic prothrombic risk factors (five patients with FII G2010A), deficiency of the physiologic clotting inhibitors (one patient), other vascular diseases (four patients), cancer (one patient).
METHODS
Venous blood was collected from the basilic vein after an overnight fasting. Venous blood samples for coagulation assays were collected into Vacutainer tubes containing 1/10 volume of 0.105 M trisodium citrate; platelet-poor plasma was obtained by centrifugation at 4000g for 10 minute and then stored frozen at -70°C until used. The investigation for the FVL mutation and FII G20210A mutation was made by venous blood samples collected into EDTA containing Vacutainer tubes; the assays were based on the reverse-hybridization principle, including three successive steps: isolation of DNA from peripheral blood, in vitro amplification of gene sequences, hybridization of the amplification products with allele specific oligonucleotides probes (Vienna Lab, Labordiagnostika GmbH, Vienna, Austria). Homocysteine was determined by enzyme immunoassay (EIA) test (Microplate Enzyme Immunoassay, Bio-Rad Laboratories Europe, Perth, UK). An elevated Hcy level was defined as greater than 15 µmol/L.
Statistics
The significance of differences observed between the groups was tested using chi-square analysis. Statistical significance was considered a P value less than .05.
RESULTS
Differences of frequencies of hyperhomocystinemia are shown in Table 2 . Hyperhomocystinemia (higher than 15 µmol/L) was documented in 24 of 49 subjects (48.9%) with RVOD and in nine of 71 healthy control subjects (12.6%). The difference in prevalence of hyperhomocystinemia was statistically significant (P < .0005) in comparison with controls.
DISCUSSION
In recent years, many scientific reports have suggested that hyperhomocystinemia may be associated with an increased risk of retinal vascular occlusive disease (RVOD), but on the other hand, further studies have not supported this relation. Homocysteine-decreasing treatment with vitamins (substitution of folic acid, pyridoxine, and cyanocobalamin) seems to reduce cardiovascular risk in patients with hyperhomocystinemia correlated to genetic defects of Hcy metabolism (10) . Moreover, Peterson and colleagues demonstrated a decreased progression of atherosclerosis after vitamin treatment in patients with unexplained atherosclerosis (11) . In our study, we found elevated Hcy levels in almost one-half of patients with RVOD. The high prevalence of hyperhomocystinemia in the patient group suggests an association between RVOD and high fasting homocystinemia, underlining the possible role of increased homocysteine levels in the pathogenesis of RVOD. The small number of patients with RVOD included in this study precluded a separate analysis of the relation between retinal vein and arterial occlusions and Hcy levels.
Our data suggest that elevated homocysteine may be an independent risk factor for retinal vascular occlusive disease, and its assessment may be important in the investigation, management, and follow-up of patients with RVOD. Nevertheless, further controlled studies are necessary to clarify the exact role of hyperhomocystinemia in RVOD and then to evaluate the appropriate therapeutic approach. Whether the risk for ocular venous occlusion is decreased by this treatment remains to be established by appropriate clinical trials. 
